True North Therapeutics progresses TNT009 towards proof of concept

Clinical stage biotech company True North Therapeutics aims to obtain proof of concept (POC) for its first-in-class monoclonal antibody TNT009 before June 2016, it has been announced.

It follows the news last week that the European Medicines Agency (EMA) had granted Orphan Drug Designation (ODD) for TNT009 for the treatment of cold agglutinin disease (CAD), a rare disease in hematology.

TNT009 selectively inhibits the classical complement pathway by targeting C1s, a serine protease within the C1-complex in the complement pathway of the immune system.